Ceftriaxone-lekko powder for injection vial 1 g N1
Condition: New product
995 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Ceftriaxone
Release form
Powder
Composition
1 bottle contains: Ceftriaxone 0.5 g and 1.0 g in the form of ceftriaxone disodium salt.
Pharmacological effect
Cephalosporin antibiotic III generation broad-spectrum. It has a bactericidal effect by inhibiting the synthesis of the bacterial cell wall. Ceftriaxone acetylates membrane-bound transpeptidases, thus disrupting the cross-linking of peptidoglycans necessary to ensure the strength and rigidity of the cell wall. It is active against aerobic, anaerobic, gram-positive and gram-negative bacteria. Resistant to the action of β-lactamase.
Pharmacokinetics
Plasma protein binding is 85-95%. Ceftriaxone is widely distributed in tissues and body fluids. Therapeutic concentrations are reached in the spinal fluid with meningitis. High concentrations are reached in bile. Gets through a placental barrier, it is allocated with breast milk in small amounts. About 40-65% of ceftriaxone is excreted in the urine unchanged. The rest is excreted in bile and feces.
Indications
Infections caused by Ceftriaxone sensitive pathogens: Sepsis, meningitis, infections of the abdominal cavity (peritonitis, inflammatory diseases of the gastrointestinal tract, biliary tract), infections of bones, joints, connective tissue, skin, infections in patients with reduced immunity, infections of the kidneys and urinary pathways, respiratory tract infections (including pneumonia), and also infections of upper respiratory tract, urogenital infections (including gonorrhea). Prevention of infections in the postoperative period.
Contraindications
Hypersensitivity to cephalosporins and penicillins. The first trimester of pregnancy.
Precautionary measures
In patients with impaired renal function, a dosage regimen is required, taking into account CC values. With caution, it is used for marked impaired renal function. In newborns with hyperbilirubinemia, especially in preterm, it may be used under strict medical supervision.
Use during pregnancy and lactation
Adequate and strictly controlled studies of the safety of ceftriaxone during pregnancy have not been conducted. The use of ceftriaxone during pregnancy and lactation is possible in caseswhen the intended benefit of therapy for the mother outweighs the potential risk to the fetus. Ceftriaxone is excreted in breast milk at low concentrations. In experimental animal studies, no teratogenic and embryotoxic effects of ceftriaxone were detected.
Dosage and administration
The drug is used intramuscularly and intravenously. For adults and for children over 12 years oldThe average daily dose is 1-2 g of ceftriaxone 1 time per day or 0.5-1 g every 12 hours. In severe cases or in cases of infections caused by moderately sensitive pathogens, The daily dose can be increased to 4 g. For newborns With a single daily dosage, the following scheme is recommended: For newborns (up to two weeks of age): 20–50 mg / kg of body weight per day (it is not recommended to exceed the dose of 50 mg / kg of body weight due to immature enzyme syst my newborn) making infants and children up to 12 letSutochnaya dose is 20-75 mg / kg tela.U children weighing 50 kg and above should be followed dosage for adults. A dose of more than 50 mg / kg of body weight should be prescribed as an intravenous infusion for at least 30 minutes. Therapy duration Depends on the course of the disease. Meningitis In bacterial meningitis in newborns and in children, the initial dose is 100 mg / kg of body weight once per day (maximum 4 g). Once a pathogen has been isolated and its sensitivity has been determined, the dose must be reduced accordingly. The best results are the following times. or allegedly infected surgery to prevent postoperative infections, Depending on the risk of infection, a single injection of ceftriaxone in a dose of 1-2 g is recommended 30-90 minutes before surgery. Renal and liver function deficiency In patients with impaired renal function, it is not necessary to reduce the dose of ceftriaxone in patients with normal liver function.Only in case of kidney failure in the preterminal stage (creatinine clearance below 10 ml / min) it is necessary that the daily dose of ceftriaxone does not exceed 2 g. In patients with impaired liver function, if the renal function is preserved, the dose of ceftriaxone is also not necessary to decrease. In cases of simultaneous the presence of severe pathology of the liver and kidney, the concentration of ceftriaxone in serum should be regularly monitored. In patients undergoing hemodialysis, there is no need to change the dose of the drug after this procedure. Intramuscular administration For intramuscular administration, 1 g of the drug must be diluted in 3.5 ml of 1% lidocaine solution and introduced into the gluteal muscle deeply, it is recommended to inject no more than 1 g of the drug into one buttock. Lidocaine solution should never be administered intravenously! Intravenous administration For intravenous injection, 1 g of the drug must be diluted in 10 ml of sterile water for injection and administered intravenously slowly over 2-4 minutes. Intravenous infusionDuration of intravenous infusion for at least 30 minutes.For intravenous infusion 2 g powder must be diluted in approximately 40 ml of a solution free from calcium, for example: in 0.9% sodium chloride solution, in 5% dextrose solution, in 10% dextrose solution, 5% fructose solution.
Side effects
Allergic reactions: urticaria, chills or fever, rash, pruritus, rarely - bronchospasm, eosinophilia, erythema polymorphic exudative (including Stevens-Johnson syndrome), serum sickness, angioedema, edema, anaphylactic shock. diarrhea or constipation, flatulence, abdominal pain, taste disturbance, stomatitis, glossitis, pseudomembranous enterocolitis, abnormal liver function (increased activity of “hepatic” transaminases, rarely - alkaline phosphatase or bilirubin, cholestatic jaundice), dysbac teriosis. From the side of hematopoietic organs: leukopenia, neutropenia, granulocytopenia, lymphopenia, thrombocytosis, thrombocytopenia, hemolytic anemia, hypocoagulation, reduction in the concentration of plasma coagulation factors (II, VII, IX, X), lengthening of the prothrombin time. renal function (azotemia, elevated blood urea, hypercreatininemia, glucosuria, cylindruria, hematuria), oliguria, anuria. Local reactions: phlebitis, vein soreness, soreness and infiltration in m ste w / o vvedeniya.Prochie: headache, dizziness, nosebleeds, candidiasis, superinfection.
Overdose
Symptoms: excitation of the central nervous system, convulsions. In case of overdose, hemodialysis and peritoneal dialysis will not reduce the concentration of the drug. There is no special antidote. Treatment: symptomatic.
Interaction with other drugs
Ceftriaxone, inhibiting the intestinal flora, interferes with the synthesis of vitamin K. Therefore, when used simultaneously with drugs that reduce platelet aggregation (NSAIDs, salicylates, sulfinpyrazone), the risk of bleeding increases. For the same reason, with simultaneous use with anticoagulants, there is an increase in the anticoagulant action. With simultaneous use with loop diuretics, the risk of nephrotoxic action increases.
special instructions
In patients with hypersensitivity to penicillins, allergic reactions to cephalosporin antibiotics are possible. They are used with caution in cases of marked renal impairment. Ceftriaxone solutions should not be mixed or administered simultaneously with other antimicrobial drugs or solutions. In infants with hyperbilirubinemia, especially in preterm, it is possible to use them. strict medical supervision.